Evidence map›Paper›PMID 41131614›Full record

ArticleBreast cancer research : BCR2025

Correction: Comparative efficacy of first- versus second-line CDK4/6 Inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.

Victoria Lis Ravani, Zahra Bagheri, Adam M Brufsky, Isabella Michelon, Ruth O'Regan, Maryam Lustberg, Hyo Han, Ming Wang, Seth A Wander

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Victoria Lis Ravani *Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.
Zahra Bagheri *Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Adam M BrufskyDivision of Hematology/Oncology, Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Magee Women's Center, Pittsburgh, PA, USA.
Isabella MichelonDivision of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Pelotas, USA.
Ruth O'ReganUniversity of Rochester Medical Center, Rochester, NY, USA.
Maryam LustbergMedical Oncology, Yale Cancer Center, Yale University, New Haven, CT, USA.
Hyo HanDepartment of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Ming WangDepartment of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Seth A WanderDivision of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School Massachusetts General Hospital, 55 Fruit St. Yawkey 9A, Boston, 02214, USA. swander@mgh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41131614
PMCPMC12548101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.